Get the Stockscreener App
7.46
2.93%
-0.225
Pre-market:
7.50
0.04
+0.54%
Cyclacel Pharmaceuticals Inc stock is traded at $7.46, with a volume of 31,127.
It is down -2.93% in the last 24 hours and down -23.96% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$7.685
Open:
$7.53
24h Volume:
31,127
Relative Volume:
0.01
Market Cap:
$16.70M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.7936
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-4.60%
1M Performance:
-23.96%
6M Performance:
+42.58%
1Y Performance:
-56.01%
1-Day Range:
$7.26
$7.59
1-Week Range:
$7.26
$8.82
52-Week Range:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
7.46 | 17.22M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
When is the best time to exit Cyclacel Pharmaceuticals Inc.2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Is Cyclacel Pharmaceuticals Inc. stock entering bullish territoryShare Buyback & Real-Time Buy Signal Notifications - Newser
Can Cyclacel Pharmaceuticals Inc. hit a new high this monthPortfolio Update Summary & High Conviction Buy Zone Alerts - Newser
Cyclacel Pharmaceuticals Enters Warrant Exchange Agreement - MSN
Is Cyclacel Pharmaceuticals Inc. still worth holding after the dipMarket Weekly Review & Weekly Momentum Picks - Newser
Technical analysis overview for Cyclacel Pharmaceuticals Inc. stockBull Run & Daily Risk Controlled Trade Plans - Newser
Using data models to predict Cyclacel Pharmaceuticals Inc. stock movementMarket Sentiment Report & Entry Point Confirmation Alerts - Newser
Can Cyclacel Pharmaceuticals Inc. ride the EV waveEarnings Overview Summary & Safe Capital Growth Plans - khodrobank.com
Is Cyclacel Pharmaceuticals Inc. stock poised for growthMarket Performance Report & Free Accurate Trade Setup Notifications - Newser
Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow
What are Cyclacel Pharmaceuticals Inc.’s earnings expectations2025 Pullback Review & Proven Capital Preservation Methods - khodrobank.com
Real time scanner hits for Cyclacel Pharmaceuticals Inc. explained2025 Institutional Moves & Accurate Entry/Exit Alerts - Newser
Has Cyclacel Pharmaceuticals Inc. formed a bullish divergence2025 Market WrapUp & Weekly Chart Analysis and Guides - Newser
Quantitative breakdown of Cyclacel Pharmaceuticals Inc. recent move2025 Key Lessons & AI Based Buy/Sell Signal Reports - Newser
Top chart patterns to watch in Cyclacel Pharmaceuticals Inc.Weekly Stock Recap & AI Powered Trade Plan Recommendations - Newser
Is a relief rally coming for Cyclacel Pharmaceuticals Inc. holdersPortfolio Profit Report & Precise Swing Trade Alerts - Newser
How moving averages guide Cyclacel Pharmaceuticals Inc. tradingJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Using R and stats models for Cyclacel Pharmaceuticals Inc. forecastingAnalyst Downgrade & Smart Allocation Stock Tips - Newser
Is Cyclacel Pharmaceuticals Inc. still a buy after recent gainsJuly 2025 Sector Moves & Daily Volume Surge Trade Alerts - khodrobank.com
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionM&A Rumor & AI Optimized Trade Strategies - Newser
What’s the fair value of Cyclacel Pharmaceuticals Inc. stockJuly 2025 Price Swings & Consistent Income Trade Recommendations - khodrobank.com
How cyclical is Cyclacel Pharmaceuticals Inc.’s revenue streamJuly 2025 Outlook & Community Verified Watchlist Alerts - khodrobank.com
Is Cyclacel Pharmaceuticals Inc. stock risky to hold nowEarnings Growth Summary & Weekly High Conviction Trade Ideas - khodrobank.com
What high frequency data says about Cyclacel Pharmaceuticals Inc.Trade Analysis Summary & Weekly Market Pulse Updates - Newser
Market reaction to Cyclacel Pharmaceuticals Inc.’s recent newsWeekly Market Summary & Target Return Focused Stock Picks - Newser
News impact scoring models applied to Cyclacel Pharmaceuticals Inc.Oil Prices & Free Technical Pattern Based Buy Signals - Newser
Cyclacel Pharmaceuticals Amends Stock Purchase Warrants - TipRanks
Cyclacel Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
Can Cyclacel Pharmaceuticals Inc. be recession proofWeekly Profit Analysis & Safe Swing Trade Setup Alerts - khodrobank.com
Is Cyclacel Pharmaceuticals Inc. stock trending bullishIPO Watch & Weekly Return Optimization Alerts - khodrobank.com
Is Cyclacel Pharmaceuticals Inc. affected by consumer sentimentQuarterly Earnings Report & Daily Chart Pattern Signals - khodrobank.com
Is Cyclacel Pharmaceuticals Inc. gaining market shareJuly 2025 Institutional & Fast Moving Stock Trade Plans - khodrobank.com
Signal strength of Cyclacel Pharmaceuticals Inc. stock in tech scannersJuly 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Tools to monitor Cyclacel Pharmaceuticals Inc. recovery probabilityJuly 2025 News Drivers & Verified Swing Trading Watchlist - Newser
What moving averages say about Cyclacel Pharmaceuticals Inc.July 2025 Market Mood & Verified Technical Trade Signals - Newser
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cyclacel Pharmaceuticals Inc Stock (CYCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lazar David E. | Interim CEO |
Feb 26 '25 |
Sale |
0.03 |
194,628,820 |
5,507,996 |
0 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):